Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for LeMaitre Vascular, Inc. (NASDAQ: LMAT), a Delaware-incorporated medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Through these filings, investors can review the company’s formal disclosures on operations, financial condition, risk factors, and governance.
LeMaitre’s SEC submissions include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present detailed financial statements, segment information, and discussions of risks such as competition, supplier dependence, regulatory compliance for devices and tissue products, international operations, product defects or recalls, litigation, and intellectual property protection. Current reports on Form 8-K, such as those referenced in the provided materials, disclose events like quarterly financial results, board decisions, and other material developments.
The company also uses its filings to describe capital markets activities, including the listing of its common stock on The Nasdaq Global Market under the symbol LMAT, the existence of convertible senior notes, dividend declarations, and share repurchase authorizations. These documents complement the non-GAAP metrics discussed in press releases by providing reconciliations and additional context for measures such as organic sales growth, adjusted margins, and EBITDA.
On Stock Titan, LeMaitre’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents like 10-Ks and 10-Qs, highlight important changes from prior periods, and clarify the implications of 8-K disclosures. Users can also review insider-related filings such as Forms 3, 4, and 5, where available, to track transactions by directors and officers. This combination of raw filings and AI-generated insights allows readers to understand LMAT’s regulatory record and financial reporting more efficiently.
LeMaitre Vascular director Lawrence J. Jasinski reported equity awards tied to performance share units. On February 26, 2026, he acquired 476 shares of common stock at no cost upon settlement of a PSU award granted on December 6, 2024, plus 1 additional common share from a derivative exercise.
The PSU award vested one‑third when the performance condition was determined satisfied on February 26, 2026, with the remaining two‑thirds vesting in equal annual installments over the next two years. Related dividend equivalent rights, economically equal to common stock, now total 2.8963 rights.
LEMAITRE VASCULAR director Joseph P. Pellegrino Jr. reported share acquisitions tied to equity compensation, not open-market buying or selling. On February 26, 2026, he received 1,893 shares of common stock as part of a performance share unit (PSU) award granted on December 6, 2024, after 25% of the award vested upon satisfaction of a performance condition.
He also acquired 4 dividend equivalent rights, which were exercised into 4 shares of common stock at a price of $0.00 per share. Each dividend equivalent right is the economic equivalent of one share of common stock and was released in connection with the PSU vesting. Following these transactions, he directly owned 12,080 shares of common stock and 11.4826 dividend equivalent rights, reflecting routine equity-based compensation rather than discretionary trading.
LeMaitre Vascular senior vice president Trent G. Kamke reported multiple equity transactions. On February 27, 2026, he completed an open-market sale of 1,044 shares of common stock at $110.29 per share, after which he directly held 6,677 common shares.
On February 26, 2026, he acquired 1,051 common shares at no cost from the settlement and partial vesting of a performance share unit award, plus 2 additional shares from related dividend equivalent rights. Also on that date, 93 shares were withheld to cover tax obligations tied to the PSU vesting.
LeMaitre Vascular (LMAT) president and director David B. Roberts reported multiple equity transactions. The largest was an open-market sale of 8,464 shares of common stock at a weighted average price of $106.8003 per share, leaving him with 17,979 shares directly owned after that sale.
On the prior day, he acquired common stock through the vesting and settlement of performance share unit (PSU) awards and related dividend equivalent rights, including grants of 1,514 shares and 146 shares at no cost, plus small amounts from dividend equivalents. The company also withheld 134 shares and 13 shares to cover tax obligations upon PSU vesting, which are reported as exempt dispositions.
LEMAITRE VASCULAR INC Chairman and CEO George W. LeMaitre reported a mix of stock sales, awards, and transfers. He sold an aggregate 205,930 shares of common stock in open-market transactions on February 26, 2026 and March 2, 2026, at weighted average prices of $106.7557 and $107.8137 per share, including sales made under a Rule 10b5-1(c) trading plan adopted on March 10, 2025.
On February 26, 2026, he received 5,609 shares upon settlement of a performance share unit award, plus 13 shares from related dividend equivalent rights, and 13 additional common shares from a derivative conversion. The company withheld 496 shares to cover tax obligations on the vesting PSUs.
On March 2, 2026, he made a bona fide gift transfer of 5,000 common shares. Separately, 33,400 shares are held by an irrevocable trust for the benefit of his children, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
LeMaitre (LMAT) reported an insider sale. The filing shows George W. LeMaitre sold 150,000 shares of common stock on 02/26/2026 for $16,013,350.00.
The Form 144 lists securities-to-be-sold entries and prior issuer-side grants and exercises; timing and other quantities are included in the filing.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice to sell Common shares of LMAT tied to restricted stock vesting under a registered plan.
The excerpt lists vesting entries and amounts by date, including 208 shares on 12/11/2024, 182 shares on 12/08/2024, 428 shares on 12/12/2024, 116 shares on 12/20/2024, and 110 shares on 12/02/2024.